# A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

> **NCT04011293** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shandong University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed or Refractory Hematological Malignancies

## Interventions

- **BIOLOGICAL:** CNCT19

## Key facts

- **NCT ID:** NCT04011293
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07
- **Primary completion:** 2020-07
- **Final completion:** 2022-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04011293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04011293, "A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04011293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*